Lyell Pharma (LYEL) - שולי רווח גולמי ממכירות

The current gross margin indicates the financial stability of Lyell Immunopharma (LYEL), where -59933.30 determines the current value of the metric. Lyell Immunopharma is implementing genetic reprogramming of T-cells to combat tumors. Its own manufacturing facility minimizes reliance on external production, while high scientific authority and liquidity ensure long-term investor confidence in the brand.
פילוחים אנליטיים ודוחות נתונים של חברת Lyell Immunopharma (LYEL)

Full laboratory capacity and the pristine condition of Lyell Immunopharma (LYEL) equipment establish a foundation for optimizing variable costs for cell products. Quarterly gross margin measures the portion of revenue minus direct production costs, allowing investors to assess cost management efficiency and the risk of expanding operating expenses by analyzing the trends on this chart.